ClinicalTrials.gg
CompletedNCT06176352POYANGUpdated Jul 31, 2026

A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

A Phase 3 interventional study of Faricimab and Ranibizumab in Choroidal Neovascularization Secondary to Pathologic Myopia, sponsored by Hoffmann-La Roche. Completed at 63 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Choroidal Neovascularization with a site in China — 2 open to participants now, 2 under way, none of them phase 3. Choroidal Neovascularization · China.

Enrollment
2nd of 11
280 · median 122
Started
2024
the only one that year
Phase 3
4 of 13
none open now
Registered
11th of 13
by date
Lead sponsor
1 of 13
Hoffmann-La Roche

Among the 13 studies in Choroidal Neovascularization with a site in China, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 4 in phase 3, and was the 11th registered.

Choroidal Neovascularization

214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.

Browse Choroidal Neovascularization studies →

Open to participants now

2 of the 13 studies in Choroidal Neovascularization with a site in China are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Choroidal Neovascularization with a site in China, or all of them as a file.
02

Study summary

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV). This non-inferiority study will compare 6.0 mg faricimab versus 0.5 mg ranibizumab administered at a pro-re-nata (PRN) dosing regimen after an initial active IVT treatment administration at randomization (Day 1).

03

Conditions studied

  • Choroidal Neovascularization Secondary to Pathologic Myopia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Treatment-naïve choroidal neovascularization (CNV) secondary to myopia
  2. Diagnosis of active myopic CNV in the study eye:

    1. Presence of high myopia, worse than -6 diopters of spherical equivalence
    2. Antero-posterior elongation measurement greater than or equal to 26.0 mm
    3. Presence of posterior changes compatible with pathologic myopia (e.g., tessellated fundus, lacquer cracks, etc.)
    4. Presence of active leakage from CNV on FFA (determined by Central Reading Centre [CRC])
    5. Presence of intraretinal or subretinal fluid or increase of CST on OCT (determined by CRC)
  3. BCVA of 78 to 24 letters, inclusive (20/32 to 20/320 approximate Snellen equivalent), using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol on Day 1
  4. Overtly healthy as determined by medical evaluation that includes medical history, physical examination, and laboratory tests
  5. Ability to comply with the study protocol, in the Investigator's judgment
  6. Other protocol-defined inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

  1. Any major illness or major surgical procedure within 1 month before screening
  2. Pregnancy or breastfeeding, or intention to become pregnant during the study or within 3 months after the final study treatment administration
  3. Uncontrolled blood pressure (systolic >180 millimetres of mercury [mmHg], diastolic >100 mmHg)
  4. Stroke (cerebral vascular accident) or myocardial infarction within 6 months prior to Day 1
  5. History of systemic or ocular disease that would contraindicate treatment with the drug or comparator
  6. Uncontrolled glaucoma in study eye
  7. Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities, including, but not restricted to, intravitreal, periocular or laser interventions in study eye
  8. Prior or concomitant periocular or intravitreal pharmacological treatment, including anti-VEGF medication, for other retinal diseases (e.g. geography atrophy, nAMD, DME etc.) in study eye
  9. Other protocol-defined exclusion criteria apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
280 participants (actual)

Study arms

  • Experimental
    Arm A: Faricimab

    All participants randomly assigned to Arm A will receive faricimab 6 mg at Day 1. Once every 4 weeks (Q4W) after Day 1, participants will receive treatment with faricimab on a pro re nata (PRN) basis dependent on prespecified retreatment criteria.

    Drug: Faricimab · Procedure: Sham Procedure

  • Active comparator
    Arm B: Ranibizumab

    All participants randomly assigned to Arm B will receive ranibizumab 0.5 mg at Day 1. Once every 4 weeks (Q4W) after Day 1, participants will receive treatment with ranibizumab on a pro re nata (PRN) basis dependent on prespecified retreatment criteria.

    Drug: Ranibizumab · Procedure: Sham Procedure

Interventions

  • Faricimab 6 mg intravitreal (IVT) injection on Day 1 with Q4W PRN treatment thereafter to Week 44. At Week 48, participants will attend a follow-up visit.

    Also known as: VABYSMO®, faricimab-svoa, RO6867461, RG7716

  • Ranibizumab 0.5 mg intravitreal (IVT) injection on Day 1 with Q4W PRN treatment thereafter to Week 44. At Week 48, participants will attend a follow-up visit.

    Also known as: Lucentis

  • ProcedureSham Procedure

    The sham is a procedure that mimics an intravitreal (IVT) injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Participants will undergo the sham procedure at study visits where no study drug is to be administered, in order to maintain masking.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Best-Corrected Visual Acuity (BCVA) Averaged Over Weeks 4, 8, and 12

    Time frame: Baseline and Average of Weeks 4, 8, and 12

Secondary outcomes

  1. Change from Baseline in BCVA Over Time

    Time frame: From Baseline through Week 48

  2. Percentage of Participants Gaining ≥15 Letters in BCVA from Baseline Averaged Over Weeks 4, 8, and 12

    Time frame: Baseline and Average of Weeks 4, 8, and 12

  3. Percentage of Participants Gaining ≥15 Letters in BCVA from Baseline Over Time

    Time frame: From Baseline through Week 48

  4. Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA from Baseline Over Time

    Time frame: From Baseline through Week 48

  5. Percentage of Participants Gaining ≥15 Letters in BCVA from Baseline or Achieving a BCVA of ≥84 Letters Over Time

    Time frame: From Baseline through Week 48

  6. Percentage of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time

    Time frame: From Baseline through Week 48

  7. Percentage of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time

    Time frame: From Baseline through Week 48

  8. Percentage of Participants Only Receiving One Injection From Baseline to Weeks 12, 24, and 48

    Time frame: From Baseline to Weeks 12, 24, and 48

  9. Number of Intravitreal Injections Received From Baseline to Weeks 12, 24, and 48

    Time frame: From Baseline to Weeks 12, 24, and 48

  10. Change from Baseline in Central Subfield Thickness (CST) of the Study Eye Averaged Over Weeks 4, 8, and 12

    Time frame: Baseline and Average of Weeks 4, 8, and 12

  11. Change from Baseline in CST of the Study Eye Over Time

    Time frame: From Baseline through Week 48

  12. Change from Baseline in Total Area of the Choroidal Neovascularization Lesion at Weeks 12 and 48

    Time frame: Baseline, Weeks 12 and 48

  13. Change from Baseline in Total Area of the Choroidal Neovascularization Leakage at Weeks 12 and 48

    Time frame: Baseline, Weeks 12 and 48

  14. Percentage of Participants with Absence of Macular Leakage at Weeks 12 and 48

    Time frame: Weeks 12 and 48

  15. Incidence and Severity of Ocular Adverse Events

    Time frame: From first dose until 35 days after the last dose of study treatment (up to 48 weeks)

  16. Incidence and Severity of Non-Ocular Adverse Events

    Time frame: From first dose until 35 days after the last dose of study treatment (up to 48 weeks)

  17. Prevalence of Anti-Drug Antibodies (ADAs) at Baseline and Incidence of ADAs During the Study

    Time frame: At Baseline and from first dose until end of study (up to 48 weeks)

07

Study locations

63 sites
  • Strathfield Retina Clinic
    Strathfield, New South Wales 2135, Australia
  • Sydney Eye Hospital
    Sydney, New South Wales 2000, Australia
  • Sydney Retina Clinic and Day Surgery
    Sydney, New South Wales 2000, Australia
  • Centre For Eye Research Australia
    East Melbourne, Victoria 3002, Australia
  • Beijing Hospital of Ministry of Health
    Beijing, 100730, China
  • Beijing Tong Ren Hospital, Capital Medical University
    Beijing, 100730, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Beijing Tsinghua Changgung Hospital
    Beijing, 102218, China
  • The Second Hospital of Jilin University
    Changchun, 130041, China
  • Zhongshan Ophthalmic Center, Sun Yat-sen University
    Guangzhou, 510060, China
  • The 2nd Affiliated Hospital of Harbin Medical University
    Harbin, 150001, China
  • Qingdao Eye Hospital of Shandong First Medical University
    Qingdao, 265299, China
  • Eye & ENT Hospital of Fudan University
    Shanghai, 200030, China
  • Shanghai First People's Hospital
    Shanghai, 200080, China
  • First Hospital of China Medical University
    Shenyang, 110001, China
  • Shanxi Eye Hospital
    Taiyuan, 030002, China
  • Tianjin Medical University Eye Hospital
    Tianjin, 300070, China
  • Eye Hospital, Wenzhou Medical University
    Wenzhou, 325027, China
  • Central Theater General Hospital of the Chinese People's Liberation Army
    Wuhan, China
  • Wuxi No.2 People's Hospital
    Wuxi, 214000, China
  • Xi'an People's Hospital (Xi'an Fourth Hospital)
    Xi'an, China
  • Chi De Creteil
    Créteil, 94010, France
  • Hopital de la croix rousse
    Lyon, 69317, France
  • Centre Paradis Monticelli
    Marseille, 13008, France
  • CHU Nantes - Hotel Dieu
    Nantes, 44093, France
  • Hopital Lariboisiere
    Paris, 75010, France
  • Fondation Rothschild
    Paris, 75940, France
  • Centres Ophtalmologique St Exupéry
    Saint-Cyr-sur-Loire, 37540, France
  • Universitatsklinikum Koln
    Cologne, 50937, Germany
  • Universitätsklinikum Freiburg, Klinik für Augenheilkunde
    Freiburg im Breisgau, 79106, Germany
  • Knappschaftsklinikum Saar GmbH
    Sulzbach, 66280, Germany
  • The University of Hong Kong
    Hong Kong, Hong Kong
  • Hong Kong Eye Hospital
    Mong Kok, Hong Kong
  • Ospedale Clinicizzato SS Annunziata
    Chieti, Abruzzo 66100, Italy
  • Policlinico di Bari
    Bari, Apulia 70124, Italy
  • Ospedale Monaldi - AORN dei Colli
    Naples, Campania 80131, Italy
  • Fondazione G.B. Bietti Per Lo Studio E La Ricerca in Oftalmologia-Presidio Ospedaliero Britannico
    Rome, Lazio 00184, Italy
  • Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico-Clinica Regina Elena
    Milan, Lombardy 20100, Italy
  • A.O. Universitaria S. Maria Della Misericordia Di Udine
    Udine, Veneto 33100, Italy
  • OFTALMIKA Sp. z o.o
    Bydgoszcz, 85-631, Poland
  • Gabinet Okulistyczny Prof Edward Wylegala
    Katowice, 40-594, Poland
  • Centrum Medyczne UNO-MED
    Krakow, 31-070, Poland
  • Klinika Okulistyczna ?Jasne Blonia? Sp. z o. o.
    Lódz, 91-134, Poland
  • Gabinet Okulistyczny Jerzy Mackiewicz
    Lublin, 20-064, Poland
  • Centrum Diagnostyki i Mikrochirurgii Oka LENS
    Olsztyn, 10-424, Poland
  • National University Hospital
    Singapore, 119074, Singapore
  • Singapore Eye Research Institute
    Singapore, 168751, Singapore
  • Asia Pacific Eye Centre
    Singapore, 258500, Singapore
  • Tan Tock Seng Hospital
    Singapore, 308433, Singapore
  • Yeungnam University Medical Center
    Daegu, 42415, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Kim's Eye Hospital
    Seoul, 07301, South Korea
  • Hospital Universitario de Bellvitge
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Complejo Hospitalario Universitario de Santiago.
    Santiago de Compostela, LA Coruna 15706, Spain
  • Hospital Universitario Puerta de Hierro
    Majadahonda, Madrid 28222, Spain
  • Clinica Universitaria de Navarra
    Pamplona, Navarre 31008, Spain
  • Hospital de la Arruzafa. Servicio de Oftalmologia
    Córdoba, 14012, Spain
  • Oftalvist
    Madrid, 28006, Spain
  • Far Eastern Memorial Hospital
    New Taipei City, 220, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • National Taiwan University Hospital
    Zhongzheng Dist., 10002, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in May 2026, 26 months.

Of 15 phase 3 interventional studies under Choroidal Neovascularization, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 35. This study's 26 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2023
First posted
Dec 19, 2023
StartActual
Mar 6, 2024
Primary completionActual
May 22, 2026
CompletionActual
May 22, 2026
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06176352
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 19, 2023
Start date
Mar 6, 2024
Primary completion
May 22, 2026
Completion
May 22, 2026
Last update
Jul 31, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Faricimab

Start the discussion